Neuroimaging findings in hospitalized patients with COVID-19

Ahmed Abdelzaher1,2, Mohammad AlQatam2, Lamyaa Alsarraf2, Mohamed H. Beheiri2, Shehata Farag Shehata4 and Nermeen A. Elsebaie1*

Abstract
Background: Variable neuroimaging findings have been reported in patients with coronavirus disease 2019 (COVID-19). In addition to respiratory symptoms, many neurologic manifestations of COVID-19 are increasingly reported and variable neuroimaging findings have been observed in patients with COVID-19. Our aim was to describe findings observed in hospitalized patients with COVID-19, presenting with acute neurologic manifestations and undergoing computed tomography (CT) or magnetic resonance imaging (MRI) of the brain.

Methods: We performed a retrospective study involving patients with laboratory-confirmed SARS-COV-2 infection, admitted to our hospital between July 1 and December 30, 2020. Patients who presented with acute neurologic symptoms and required neuroimaging were only included in the study. Neuroimaging examinations were evaluated for the presence of infarction, hemorrhage and encephalopathy. The frequency of these findings was correlated with clinical variables, including presence of comorbidities, requirement for intensive care unit admission, and duration between admission and onset of neurologic signs and symptoms as documented in the hospital medical records.

Results: A total of 135 patients underwent at least one cross-sectional imaging of the brain, the median age of these patients was 63 years, and 72% were men. Disturbed level of consciousness was the most common neurologic symptom (80.7%). Acute neuroimaging findings were found in 34 patients (25.2%) including; acute ischemic infarcts (16/135; 11.9%), intracranial hemorrhages (9/135, 6.7%), cerebral venous thrombosis (2/135; 1.5%), posterior reversible encephalopathy syndrome (1/135; 0.7%), and hypoxic-ischemic encephalopathy (6/135, 4.4%). There was no statistically significant difference in patient age (p = 0.062), sex (p = 0.257), presence of comorbidities (p = 0.204), intensive care unit admission (p = 0.326) and duration between admission and onset of neurologic signs and symptoms (p = 0.755), in patients with positive versus negative neuroimaging studies.

Conclusions: Our study showed that cerebrovascular complications, ischemic and hemorrhagic were the most frequent imaging finding in hospitalized patients with COVID-19. Knowledge about these potentially serious complications can help optimize management for these patients.

Keywords: Corona virus disease 19, Ischemic infarcts, Venous sinus thrombosis, Posterior reversible encephalopathy syndrome

*Correspondence: Nermeen.elsebaie@alexmed.edu.eg; Nermeenmonsef@yahoo.com
1 Diagnostic and Interventional Radiology Department, Alexandria Faculty of Medicine, Alexandria University, Shampillon street, Alexandria 21131, Egypt
Full list of author information is available at the end of the article
in the upper airway, and in a good percentage of cases, it is cleared by the immune system, causing only minimal symptoms. In more vulnerable individuals, the virus affects the lower respiratory tract resulting in more severe illnesses such as pneumonia and severe respiratory distress syndrome [2].

In addition to respiratory symptoms, many neurologic manifestations of COVID-19 are increasingly reported, including headache, dizziness, confusion, seizures, and focal neurologic deficits [3–8]. Variable neuroimaging findings have been reported in patients with COVID-19 including ischemic infarct, hemorrhage, acute hemorrhagic necrotizing encephalopathy, cerebral venous thrombosis, and diffuse leukoencephalopathy with microhemorrhages [9–13].

It was found that SARS-CoV-2 shows a high affinity for the angiotensin-converting enzyme 2 (ACE2) receptor, which is expressed in the epithelium of the upper and lower airways, as well as the endothelium of the capillaries including those in the central nervous system [14]. At the same time, COVID-19 patients, especially severe cases, frequently present severe systemic manifestations such as viremia, hypoxia, cytokine storm, and coagulopathy. It is still not clear if neurologic symptoms and different neuroimaging finding result from these systemic changes or direct effects of the virus itself [15].

Our study aimed to describe variable neuroimaging findings observed in hospitalized patients with COVID-19. This may provide valuable insight into coronavirus pathogenesis and guide the early detection and treatment of neurologic diseases associated with COVID-19 infection.

**Methods**

This retrospective study was approved by the institutional review board. Informed consent was waived. The study was conducted in our tertiary care hospital which is assigned to treat patients with COVID-19. We retrospectively reviewed all patients admitted between July 1 and December 30, 2020. All cases were confirmed to have COVID-19 by acquiring real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis for SARS-CoV-2 of throat swab specimens. Patients presented with acute neurologic symptoms and required neuroimaging were only included in the study. Data were collected from hospital medical records include age, sex, acute neurologic symptoms, presence of comorbidities, duration between admission and onset of neurologic signs and symptoms and intensive care unit (ICU) admission.

**Imaging technique**

All computed tomography (CT) examinations were obtained on a 128-section multidetector-row CT scanner (Revolution Frontier, GE Healthcare). Axial non-contrast CT studies of the head were acquired with 120-kV, automatically adjusted mAs and 0.625–1.25 mm section thickness. Imaging was obtained from the level of the skull base to the vertex. Coronal and sagittal reformats with 2-mm-thick slices were reconstructed. For CT angiography (CTA) of the head and neck; images were obtained from the level of the aortic arch through the vertex, with a slice thickness of 0.625 after injection of a dose of 80–100 mL of iodinated contrast material (320 mg/ mL) using a power injector at a rate of 4–5 mL/s. For CT venography (CTV), craniocaudal scanning was done, with a manual start when the veins are clearly visible below the skull base. Coronal and sagittal reformats with 2-mm-thick slices were reconstructed. MR imaging examinations of the brain were obtained on a 1.5 T scanner (Signa, GE Healthcare). For MR imaging; sequences performed included axial T1-weighted imaging (T1WI), axial T2 fluid-attenuation inversion recovery (FLAIR), axial T2WI, axial diffusion weighted imaging (DWI), axial susceptability-weighted imaging (SWI), and sagittal T1WI. Gadopentetate dimeglumine (0.1 mmol/ kg) was used for contrast material-enhanced studies.

**Image evaluation**

All CT and MR imaging examinations obtained during the hospitalization of patients for COVID-19 were reviewed by two neuroradiologists (A.A., N.E.; 18 and 11 years of experience, respectively). Acute neuroimaging findings, including the presence of acute or subacute infarction, hemorrhage, and encephalopathy were recorded. For acute or subacute infarctions, the location and vascular territory of the infarct were recorded. For intracranial hemorrhages, the compartment of intracranial hemorrhage (parenchymal, subarachnoid, subdural or intraventricular) was defined. Posterior reversible encephalopathy syndrome (PRES) was determined by the presence of confluent T2-FLAIR hyperintensity at MRI [16]. Hypoxic-ischemic encephalopathy (HIE) was suggested at CT if there is diffuse cerebral edema with loss of normal gray-white differentiation, and at DWI when there is restricted diffusion in the basal ganglia or cerebral cortex [17]. At CTA and CTV, the location and extent of thrombosis whether arterial or venous were reported. Chronic findings, including chronic infarcts or white matter changes likely of microvascular origin based on the age of the patient, were considered incidental and not recorded.

**Data analysis**

Data were described using frequency and proportion for categorical variables and using mean and range for quantitative data. Two-tailed t test was performed to evaluate
significant difference in patient age for patients with positive versus negative neuroimaging findings. Chi-squared and Mann–Whitney U tests were used to measure associations between neuroimaging findings and clinical parameters including presence of previous comorbidities, intensive care unit admission and duration between admission and onset of neurologic signs and symptoms. A p value of less than 0.05 was considered statistically significant.

Results
Patient characteristics
A total of 135 patients met the inclusion criteria of the study, the age range was 21–88 years, the median age was 63 years, 97 were males and 38 were females. Regarding the presence of comorbidities, 95 (95/135; 70.4%) had at least one of the following chronic disorders: hypertension (73/135; 54%), diabetes (63/135; 46.7%), coronary artery disease (13/135; 9.6%) and cerebrovascular disease (2/135; 1.5%). Among 135 patients, 90 of them (66.7%) required ICU admission. The most common neurologic symptoms were disturbed level of consciousness in 109 patients (109/135; 80.7%), focal neurologic deficit in 19 patients (19/135; 14.1%), headache in 5 patients (5/135; 3.7%), visual disturbances in 4 patients (4/135; 3%), seizures in 2 patients (2/135; 1.5%), ataxia in 1 patient (1/135; 0.7%), neck stiffness in 1 patient (1/135; 0.7%), behavioral changes and agitation in 1 patient (1/135; 0.7%).

Non-contrast CT of the brain was done in 135 cases, and MRI of the brain was done in 8 patients. MRI with contrast was performed in one patient. Regarding neurovascular imaging, 7 patients had CTA of the head and neck arteries and 12 patients had CTV of the cerebral veins. Of 135 patients with neuroimaging studies; 34 patients had acute neuroimaging findings (34/135; 25.2%) and 101 patients (101/135; 74.8%) had either normal scan or chronic findings. The demographic and clinical data of all patients are illustrated in Table 1.

Among 34 patients with acute neuroimaging findings, the age range was 33–83 years, the median age was 60 years, 27 were males and 7 were females. The most common neurologic symptoms were disturbed level of consciousness in 26 patients (26/34; 76.5%), focal neurologic deficit in 9 patients (9/34; 26.5%) and seizures in 2 patients (2/34; 5.9%). Of the 34 patients, 13 patients had no known past medical history (13/34; 38.2%) and 21 (21/34; 61.8%) had at least one of the following chronic disorders: hypertension (10/34; 29.4%), diabetes (10/34; 29.4%), coronary artery disease (1/34; 2.9%).

Table 1 Demographic and clinical data of patients with COVID-19 and acute neurologic manifestations who underwent neuroimaging

|                                | Total patients underwent neuroimaging (total number = 135) | Patients without acute neuroimaging findings (total number = 101) | Patients with acute neuroimaging findings (total number = 34) |
|--------------------------------|-----------------------------------------------------------|-------------------------------------------------------------------|-------------------------------------------------------------|
| **Age range**                   | 21–88                                                     | 21–88 years                                                       | 33–83 years                                                 |
| **Male patients**               | 97                                                        | 70                                                                | 27                                                          |
| **Number of patients with comorbidities** | 95                                                        | 74                                                                | 21                                                          |
| **Hypertension**                | 73                                                        | 63                                                                | 10                                                          |
| **Diabetes**                    | 65                                                        | 55                                                                | 10                                                          |
| **Coronary disease**            | 13                                                        | 12                                                                | 1                                                           |
| **Cerebrovascular disease**     | 2                                                         | 1                                                                 | 1                                                           |
| **Neurologic manifestations**   |                                                           |                                                                    |                                                             |
| Disturbed level of consciousness| 109                                                       | 83                                                                | 26                                                          |
| Focal neurologic deficit        | 19                                                        | 10                                                                | 9                                                           |
| Seizures                        | 2                                                         | –                                                                 | 2                                                           |
| Headache                        | 5                                                         | 5                                                                 | –                                                           |
| Visual symptoms                 | 4                                                         | 4                                                                 | –                                                           |
| Ataxia                          | 1                                                         | 1                                                                 | –                                                           |
| Behavioral changes              | 1                                                         | 1                                                                 | –                                                           |
| Neck stiffness                   | 1                                                         | 1                                                                 | –                                                           |
| ICU admission                   | 90                                                        | 65                                                                | 25                                                          |
| **Imaging examination**         |                                                           |                                                                    |                                                             |
| CT                              | 135                                                       | 101                                                               | 34                                                          |
| MRI                             | 8                                                         | 5                                                                 | 3                                                           |
and cerebrovascular disease (1/34; 2.9%). Out of 34 patients with acute imaging findings, 25 patients (25/34; 73.5%) required ICU admission for hypoxic respiratory failure, all of them were on mechanical ventilation except one patient required extracorporeal membrane oxygenation (ECMO).

**Imaging findings**

Acute neuroimaging findings were detected in 34 patients (34/135; 25.2%); 16 patients (16/135; 11.9%) developed acute ischemic infarcts, nine patients (9/135, 6.7%) had intracerebral hemorrhage, two patients (2/135; 1.5%) had venous sinus thrombosis, one with posterior reversible encephalopathy syndrome (PRES) (1/135; 0.7%), and six patients (6/135, 4.4%) with hypoxic-ischemic encephalopathy pattern. Acute imaging findings are illustrated in Table 2.

**Acute ischemic infarcts**

Among 16 patients with ischemic stroke, 13 infarcts involved the anterior circulation and 3 were in the posterior circulation. Large territorial infarcts (involving the whole vascular territory) were seen in 9 patients, 6 in the middle cerebral artery (MCA) territory (Fig. 1), 2 in the anterior cerebral artery (ACA) territory and one in a posterior cerebral artery (PCA) territory. CTA of the neck was done in one patient and revealed acute right internal carotid artery (ICA) thrombus without evidence of

**Table 2** Neuroimaging findings of hospitalized patients with new onset of neurologic symptoms following COVID-19

| Imaging findings                          | Number of patients (total number = 34) |
|------------------------------------------|---------------------------------------|
| Acute ischemic infarcts                  | 16 (47%)                              |
| Middle cerebral artery territory         | 10                                    |
| Anterior cerebral artery territory       | 3                                     |
| Posterior cerebral artery territory      | 3                                     |
| Intracranial hemorrhage                  | 9 (26.5%)                             |
| Parenchymal                               | 8                                     |
| Subdural                                  | 1                                     |
| Subarachnoid                              | 2                                     |
| Intraventricular                          | 2                                     |
| Cerebral venous thrombosis               | 2 (6%)                                |
| Posterior reversible encephalopathy syndrome | 1 (2.9%)                           |
| Hypoxic-ischemic encephalopathy          | 6 (17.6%)                             |

Fig. 1  Acute ischemic infarct. 49-year-old man with COVID-19 transferred to ICU for mechanical ventilation, his neurologic condition suddenly deteriorated and the patient was found with bilaterally fixed and dilated pupils. a Axial CT image demonstrating large left MCA infarction. b Hyperdense left MCA is seen the proximal M1 segment of the left MCA (arrow), suggesting thrombus
intra or extracranial atherosclerotic disease (Fig. 2). Out of these 16 patients, 4 patients were less than 50 years of age (36, 38, 43, 49 years) and had no previous comorbidities. Twelve patients had pre-existing vascular risk factors (6 had diabetes, 7 had hypertension, and 1 patient had coronary artery disease). Out of 16 patients, 11 of them required ICU admission and mechanical ventilation for hypoxic respiratory failure.

Intracerebral hemorrhages
Nine patients had evidence of intracranial hemorrhage on non-contrast CT of the brain. Of these, 8 patients had a parenchymal hemorrhage and one patient had isolated subarachnoid hemorrhage (SAH) (Fig. 3). Out of the 8 patients with parenchymal hemorrhages, one had associated subdural hemorrhage (SDH) and intraventricular hemorrhage (IVH) and one patient had SAH and IVH. The size of the parenchymal hematomas exceeded 5 cm in 4 patients. Two hematomas showed blood-fluid levels (Fig. 4). Three of the patients with large parenchymal hemorrhages showed evidence of diffuse hypoxic-ischemic injury. Five patients out of 9 with ICH had previous vascular risk factors (3 had diabetes and hypertension and one patient had hypertension). The remaining 4 patients had no previous comorbidities and were less than 50 years. Of the 9 patients with intracranial hemorrhage, 7 were critically ill and admitted to the ICU on mechanical ventilation, and one of them was treated with extracorporeal membrane oxygenation (ECMO). All of them were under prophylactic anticoagulation except one patient who received therapeutic anticoagulation for myocardial infarction developed during his hospital stay.

Cerebral venous thrombosis
Cerebral venous sinus thrombosis was diagnosed in two patients; first case was a 60-year-old man with extensive dural sinus thrombosis involving the superior sagittal sinus, bilateral transverse, and sigmoid sinuses, as well as the left cavernous sinus extending to left superior ophthalmic vein complicated by bilateral frontal hemorrhagic venous infarction (Fig. 5); the patient was discharged around 2 weeks ago from our hospital following a short and uneventful admission for COVID-19, presented again to our emergency department with confusion. He has no other obvious risk factors for thrombosis. Second case was a 60-year-old man admitted to ICU for hypoxic respiratory failure on mechanical ventilation, CT brain was done for the sudden deterioration in the level of consciousness, and CTV revealed dural sinus thrombosis at right sigmoid sinus extending below skull base to right internal jugular vein (IJV).

Posterior reversible encephalopathy syndrome (PRES)
The study included one case of PRES, (47-year-old man) was admitted to the ICU and developed acute hypertension and generalized tonic colonic convulsions for the first time during his intensive care stay. Initial CT showed bilaterally Parieto-occipital hypodensity and MRI revealed parieto-occipital and superior frontal confluent T2 and FLAIR hyperintensities (Fig. 6) without diffusion restriction or blooming at SWI.

Hypoxic-ischemic encephalopathy
Hypoxic-ischemic encephalopathy was seen in 6 patients admitted to ICU with a history of cardiopulmonary arrest. CT done in 4 patients revealed diffuse brain edema with lost gray-white matter differentiation. MRI done in two patients showed signs of severe hypoxic-ischemic brain injury of the deep gray nuclei with diffusion restriction involving the basal ganglia and thalami (Fig. 7).

Correlation analysis
There was no statistically significant difference in patients’ age ($p = 0.062$), sex ($p = 0.257$), presence of comorbidities ($p = 0.204$), ICU admission ($p = 0.326$).
and duration between admission and onset of neurologic signs and symptoms ($p=0.755$) in patients with positive versus negative neuroimaging studies (Table 3).

**Discussion**

The mechanism of neurologic complications in patients with COVID-19 is complex and multifactorial. As the COVID-19 pandemic continues to progress, cerebrovascular manifestations of COVID-19 became more evident. Although COVID-19 has been observed to affect the respiratory system primarily, neurologic involvement has already been reported [18]. In the present study, a number of patterns in the brain CT and MRI were seen. On CT, patterns consisted of acute/subacute infarcts, parenchymal, subdural, and subarachnoid hemorrhage. On CTA and CTV, carotid artery thrombus and venous sinus thrombosis were seen. On MRI, hypoxic-ischemic changes and PRES changes were detected.

A total of 135 patients developed acute neurologic manifestation and underwent neuroimaging with either CT, MR imaging, or both, 25.2% of them had acute imaging findings. Ischemic stroke (11.9%) was the most common acute finding. Several hypotheses suggested that the pathogenesis of stroke in COVID-19 may be attributed to the development of coagulopathy or endothelial dysfunction [9, 14]. Systemic inflammation and cytokine storm triggers the coagulation system with subsequent development of a hypercoagulable state. In addition, this inflammatory state can damage the capillary endothelium resulting in dysregulation of its anti-thrombotic properties. Both coagulopathy and endothelial dysfunction account for the increased risk of thrombotic disease involving either the arterial or venous circulations in patients with COVID-19. Moreover, patients with COVID-19 hospitalized in intensive care units are at higher risk of venous and arterial thrombotic events despite prophylactic anticoagulation [15, 19].

Cerebrovascular events (both ischemic and hemorrhagic) were found to be the most common neuroradiologic abnormality seen among COVID-19 patients [20]. In our study, 11.9% patients developed acute ischemic infarcts. Chougar et al. [21] reported acute ischemic infarcts in 7.6% of patients with acute neurologic manifestations. In a study of 108 hospitalized COVID-19 patients who underwent neuroimaging, 31% demonstrated acute ischemia [22]. As in other series [23], most of our patients with ischemic infarcts (12/16) had cerebrovascular comorbidities, like hypertension and diabetes. However, growing evidence suggests that COVID-19 is associated with acute stroke, even in patients at low risk for stroke. Four out of 16 patients with ischemic stroke in our study were less than 50 years of age and had no previous comorbidities. Oxley et al. [24] reported five
cases of stroke in patients younger than 50 who had no previous medical history.

Large territorial infarcts were seen in 9 patients in the current study. Kihira et al. [25] found that patients with COVID-19 had large vessel occlusion stroke risk 2.4 times that of patients without COVID-19 after control for race and ethnicity in his multivariate analysis. Our experience supports other observations of patients with COVID-19 developing acute stroke secondary to acute thrombus within the internal carotid artery. Gulko et al. [26] illustrated two cases with imaging findings of acute thrombus at the proximal internal carotid arteries without other signs of intra- or extracranial atherosclerotic disease similar to our case.

In addition to arterial thrombosis, several studies have observed high rates of venous thromboembolism in critically ill patients with COVID-19 who otherwise lack the classic risk factors for venous thromboembolism [19, 27]. In our study, two patients developed cerebral venous thrombosis (CVT), one of them was admitted to the ICU on mechanical ventilation for hypoxic respiratory failure. Both patients had dural sinus thrombosis. In general, the most common predisposing factor of dural sinus thrombosis is hypercoagulability in the context of a prothrombotic condition which is, in our cases, possibly induced by SARS-COV2 infection. Early identification is critical because prompt anticoagulation can improve outcomes, as it is a potentially reversible condition. As CVT is one of the few causes of cerebral hemorrhage that call for anticoagulation therapy, diagnostic certainty is important so that appropriate treatment can be started. Diagnosis
is difficult because the clinical manifestations of CVT are nonspecific, such as headache, seizures, decreased level of consciousness, and focal neurologic deficits. For this reason, imaging is crucial to diagnosis, and radiologists must be able to identify the findings that raise suspicion of CVT (anticoagulation therapy) early to avoid complications and even death [28, 29]. Intracranial hemorrhage (ICH) reported in patients with COVID-19 is a devastating event. Therapeutic anticoagulation is usually initiated to treat thrombotic
complications such as deep vein thrombosis, pulmonary embolism, stroke, and acute myocardial infarction [30]. Patients with COVID-19 who develop the severe disease may have a series of complications such as renal failure or liver dysfunction, which can affect both venous thromboembolism and bleeding status. Regular monitoring and adjustment of thromboprophylaxis is crucial to prevent complications [30]. In the current study, 6.7% of patients with acute neurologic symptoms had intracerebral hemorrhage. In one study [31], 4.4% of patients with neuroimaging had ICH, the majority of them received therapeutic anticoagulation. Radmanesh et al. [32] reported acute intracranial hemorrhage in 4.5% of patients with acute neurologic symptoms. ICH secondary to anticoagulation therapy is an important iatrogenic complication. The blood-fluid level was seen in two patients in our series. This is caused by the dependent separation of heavier blood from a lighter serous fluid. This neuroimaging finding is characteristic for patients who have been treated with anticoagulants [33]. In our cases, one patient received therapeutic anticoagulation for acute myocardial infarction, a complication that issued during his hospital stay and the other patient had prophylactic anticoagulation. We reported only one case of isolated convexity SAH at high parietal regions bilaterally. Nawabi et al. [34] found isolated cortical SAH to be the most frequent hemorrhage type in their study most of them localized along the convexity.

PRES was suggested diagnosis in one case with acute hypertension and seizures during his ICU stay. Patients with PRES can present clinically by headache, visual disturbances, disturbed level of consciousness, or seizures. At MRI, it appears as edema involving the cortex and subcortical white matter commonly at the parieto-occipital lobes but may be atypically seen at the frontal and temporal lobes, brainstem or cerebellum. It usually appears bilateral and asymmetric, without diffusion restriction [35]. In patients with COVID-19, PRES can be explained in relation to multiple risk factors. The cytokine storm of COVID-19 causes endothelial dysfunction leading to increased permeability of the blood–brain barrier (BBB) rendering susceptible to blood pressure changes. Renal failure is a common complication associated with critically ill patients with COVID-19 could be another explanation [36–38].

In a study by Yoon et al. [39], the prevalence of ICU admission and intubation was significantly higher for patients with acute neuroimaging findings than for patients without acute neuroimaging findings. In the current study, number of patients requiring ICU admission was higher among those with acute neuroimaging finding (73.5%) than patients without acute neuroimaging findings (64.4%), however, this difference was not statistically significant ($p = 0.326$).

This study has some limitations, first, the main imaging modality in our study was non-contrast CT of the brain. Only a few cases underwent MRI. MRI is known to have better sensitivity than CT but similar to other policies worldwide, MR imaging use was limited to patients with COVID-19 with the highest clinical urgency. Second, CSF analysis was not done in our patients. This procedure was limited during the pandemic to avoid the risk of cross-infection from invasive procedure and the risk of complications including bleeding as many patients are on anticoagulant therapy. Third, this study had inherent limitations related to its retrospective nature. Further prospective studies are recommended.

Conclusions
As the novel coronavirus pandemic spreads, neurologic complications are increasingly recognized, and understanding the exact underlying mechanism is still challenging. Of our patients with COVID-19 undergoing neuroimaging, we observed ischemic strokes and intracranial hemorrhages were the most frequent imaging findings. Familiarity with these potentially serious complications can help optimize the management of patients with COVID-19 with neurologic

Table 3  Comparison between patients with coronavirus disease 2019 with and without acute neuroimaging findings

|                                      | Acute neuroimaging findings | No acute neuroimaging findings | Statistical significance |
|--------------------------------------|-----------------------------|--------------------------------|--------------------------|
| Number of patients (%)               | 34 (25.2%)                  | 101 (74.8%)                   | –                        |
| Mean age ± SD                        | 58±13.4                     | 63.1 ± 13.9                   | 0.062                    |
| Gender, n (%)                        | 27 males (79.4%)            | 70 males (69.3%)              | 0.257                    |
| Presence of comorbidities, n (%)     | 21 (61.8%)                  | 74 (73.3%)                    | 0.204                    |
| Intensive care unit admission, n (%) | 25 (73.5%)                  | 65 (64.4%)                    | 0.326                    |
| Duration between admission and onset of neurologic signs and symptoms, mean (days)± SD | 19±15.9                     | 15.9±10.5                     | 0.755                    |

SD standard deviation
manifestations. Future prospective studies would help to establish treatment guidelines in these critical cases.

Abbreviations
COVID 19: Coronavirus disease 2019; SARS-CoV: Severe acute respiratory syndrome-related coronavirus; ACE2: Angiotensin-converting enzyme 2; RT-PCR: Real-time reverse transcription-polymerase chain reaction; ICU: Intensive care unit; CT: Computed tomography; CTV: CT venography; CTA: CT angiography; MRI: Magnetic resonance imaging; T1WI: T1-weighted imaging; FLAIR: Fluid-attenuation inversion recovery; DWI: Diffusion weighted imaging; SWI: Susceptibility-weighted imaging; PRES: Posterior reversible encephalopathy syndrome; HIE: Hypoxic-ischemic encephalopathy; ECMO: Extracorporeal membrane oxygenation; MCA: Middle cerebral artery; ACA: Anterior cerebral artery; PCA: Posterior cerebral artery, ICA: Internal carotid artery; SAH: Subarachnoid hemorrhage; SDH: Subdural hemorrhage; IVM: Intraventricular hemorrhage; JV: Internal jugular vein; CVT: Cerebral venous thrombosis; ICH: Intracranial hemorrhage.

Acknowledgements
Not applicable.

Authors' contributions
NE (the corresponding author) is responsible for ensuring that the descriptions are accurate and agreed by all authors. NE, AA, MA and LA had made substantial contributions to all of the following: (1) Design of radiological work, (2) Drafting the work and revising it. NE, AA had made substantial contributions to all of the following: (1) Design of radiological work, (2) Analysis and interpretation of radiological data, (3) Drafting the work and revising it. MB had made substantial contributions to: (1) Collection of clinical data, and (2) Drafting the work. SS had made statistical analysis of the results. All authors approved the final manuscript. All authors have agreed both to be personally accountable for the author’s own contributions and to ensure that questions related to the accuracy or integrity of any part of the work, even ones in which the author was not personally involved, are appropriately investigated, resolved, and the resolution documented in the literature. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Approval for this study was obtained from the Research Ethics Committee of Kuwait ministry of health, Assistant undersecretary for planning and quality (1711/2021). All study procedures were carried out in accordance with the Declaration of Helsinki regarding research involving human subjects.

Consent for publication
Patient consent was waived in this retrospective study by the Research Ethics Board, assuring respect of both patient and medical records confidentiality.

Competing interests
None.

Author details
1 Diagnostic and Interventional Radiology Department, Alexandria Faculty of Medicine, Alexandria University, Shampilon street, Alexandria 21131, Egypt. 2 Medical Imaging Department, Mubarak Al-Kabeer Hospital, Ministry of Health, Kuwait City, Kuwait. 3 Medical Imaging Department, Ibn Sina Hospital, Ministry of Health, Kuwait City, Kuwait. 4 Medical Statistics and Biomedical Informatics Department, High Institute of Public Health, Alexandria University, Alexandria, Egypt.

References
1. Desforges M, Le Coupenc A, Dubeau P, Bourguoin A, Lajoie L, Dubé M et al (2019) Human Coronavirus and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses 12(1):14
2. Oudkerk M, Bürker H, Kuijpen D, van Es N, Oudkerk S, McCloud T et al (2020) Diagnosis, prevention, and treatment of thrombomembolic complications in COVID-19: Report of the National Institute for Public Health of the Netherlands. Radiology 297(1):E216–E222
3. Zhou Z, Kang H, Li S, Zhao X (2020) Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms. J Neurol 267(8):2179–2184
4. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q (2020) Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China JAMA Neurol 77(6):683–690
5. Karadag O, Öztürk B, Sonkaya AR (2020) A prospective clinical study of detailed neurological manifestations in patients with COVID-19. Neurrol Sci 41(8):1991–1995
6. Portela-Sánchez S, Sánchez-Solchero A, Melgarejo Otalora P, Rodríguez López A, Velilla Alonzo G, Palacios-Mendoza MA et al (2021) Neurological complications of COVID-19 in hospitalized patients. The registry of a neurology department in the first wave of the pandemic. Eur J Neurol 28(10):3339–3347
7. Wang L, Shen Y, Li M, Chuang H, Ye Y, Zhao H, Wang H (2020) Clinical manifestations and evidence of neurologic involvement in 2019 novel coronavirus SARS-CoV-2: a systematic review and meta-analysis. J Neurol 267(10):2777–2789
8. Harapan BN, Yoo HJ (2021) Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19). J Neurol Sci 408(9):3059–3071
9. Kremer S, Lersv F, Anheim M, Mordj H, Schenck M, Oesterle H et al (2020) Neurologic and neuroimaging findings in patients with COVID-19: A retrospective multicenter study. Neurology 95(13):e1868–e1882
10. Moonis G, Filippi CG, Kirsch CFE, Mohan S, Stein EG, Hirsch JA et al (2021) The spectrum of neuroimaging findings on CT and MRI in adults with COVID-19. AJR Am J Roentgenol 217(4):959–974
11. Choi Y, Lee MK (2020) Neuroimaging findings of brain MRI and CT in patients with COVID-19: a systematic review and meta-analysis. Eur J Radiol 133:109939
12. Ladopoulos T, Zand R, Shahjoeu S, Chang JJ, Motte J, Charles James J et al (2021) COVID-19: neuroimaging features of a pandemic. J Neuroimaging 31(2):228–243
13. Nichollson P, Alshafai L, Kring T (2020) Neuroimaging findings in patients with COVID-19. AJR Am J Neuroradiol 41(8):1380–1383
14. Jensen-Kondering U, Neumann A, Margraf NG, Gövert F, Brüggemann N, Schunk D et al (2021) Cerebral imaging in patients with COVID-19 and neurological symptoms: first experience from two university hospitals in Northern Germany. Refo 193(6):667–671
15. Lang M, Li MZ, Buch K, Yoon BC, Applewhite BP, Leslie-Mazwi TM et al (2020) Risk of acute cerebrovascular events in patients with COVID-19 infection. AJR Am J Neuroradiol 41(11):E92–E93
16. Bartynski WS, Boardman JF (2007) Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 28(7):1320–1327
17. Hung BI, Castillo M (2008) Hypoxic ischemic brain injury: imaging findings from birth to adulthood. Radiographics 28(2):417–439
18. Asadi-pooya AA, Simani L (2020) Central nervous system manifestations of COVID-19: a systematic review. J Neurol Sci 413:116832
19. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers D, Kant KM et al (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147
20. Katal S, Balakrishnan S, Ghoharamezianehad A (2021) Neuroimaging and neurologic findings in COVID-19 and other coronavirus infections: a systematic review in 116 patients. AJR Am J Neuroradiol 48(1):43–50
21. Chougar L, Shor N, Weiss N, Galanaud D, Leclercq D, Mathon B et al (2020) Retrospective observational study of brain magnetic resonance imaging findings in patients with acute SARS-CoV-2 infection and neurological manifestations. Radiology 297(3):E313–E323
22. Mahammedi A, Saba L, Vagal A, Leali M, Rossi A, Gaskill M et al (2020) Imaging in neurological disease of hospitalized COVID-19 patients: an Italian multicenter retrospective observational study. Radiology 297(2):E270–E273
23. Franceschi AM, Arora R, Wilson R, Giliberto L, Libman RB, Castillo M (2020) Neurovascular complications in COVID-19 infection: case series. AJNR Am J Neuroradiol 41(9):1632–1640
24. Oxl ey T, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP et al (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. N Engl J Med 382:e60–e64
25. Khaira S, Schefflein J, Mahmoudi K, Rigney B, Delman N, B, Mocco J, et al (2020) Association of Coronavirus Disease (COVID-19) with large vessel occlusion strokes: a case-control study. AJR Am J Roentgenol 291–6
26. Gulko E, Gomes W, Ali S, Al-Mufti F, Mehta H (2020) Acute common carotid artery bifurcation thrombus: an emerging pattern of acute strokes in patients with COVID-19? AJNR Am J Neuroradiol 41(8):E65–E66
27. Jain R, Young M, Dogra S, Kennedy H, Nguyen V, Jones S et al (2020) COVID-19 related neuroimaging findings: a signal of thromboembolic complications and a strong prognostic marker of poor patient outcome. J Neurol Sci 414:116923
28. Chougar L, Mathon B, Weiss N, Degos V, Shor N (2020) Atypical deep cerebral vein thrombosis with hemorrhagic venous infarction in a patient positive for COVID-19. AJNR Am J Neuroradiol 41(8):1377–1379
29. Canedo-Antelo M, Baleato-Gonzalez S, Mosqueira A, Casas-Martinez J, Oleaga L, Vilanova JC et al (2019) Radiologic clues to cerebral venous thrombosis. Radiographics 39:1611–1628
30. Lin E, Lantos JE, Strauss SB, Phillips CD, Campion TR Jr, Navi BB et al (2020) Brain imaging of patients with COVID-19: findings at an academic institution during the height of the outbreak in New York City. AJNR Am J Neuroradiol 41(1):2001–2008
31. Dogra S, Jain R, Cao M, Bilaloglu S, Zagzag D, Hochman S et al (2020) Hemorrhagic stroke and anticoagulation in COVID-19. J Stroke Cerebrovasc Dis 29(8):104984
32. Radmanesh A, Raz E, Zan E, Derma A, Kaminetzky M (2020) Brain imaging use and findings in COVID-19: a single academic center experience in the epicenter of disease in the United States. AJNR Am J Neuroradiol 41(7):1179–1183
33. Wee NK, Fan EB, Lee KCH, Chia YW, Lim TCC (2020) CT fluid-blood levels in COVID-19 intracranial hemorrhage. AJNR Am J Neuroradiol 41(9):E76–E77
34. Nwabu J, Morotti A, Wildgruber M, Boulouis G, Kraehling H, Schlunk F et al (2020) Clinical and imaging characteristics in patients with SARS-CoV-2 infection and acute intracranial hemorrhage. J Clin Med 9(8):2543
35. Franceschi AM, Ahmed O, Giliberto L, Castillo M (2020) Hemorrhagic posterior reversible encephalopathy syndrome as a manifestation of COVID-19 infection. AJNR Am J Neuroradiol 41(7):1173–1176
36. Parauda S, Gaoa V, Gewirtz N, Parikh NS, Merkler AE, Lantos J et al (2020) Posterior reversible encephalopathy syndrome in patients with COVID-19. J Neurol Sci 416:117019
37. Goldberg MF, Goldberg MF (2020) Neuroradiologic manifestations of COVID-19: what the emergency radiologist needs to know. Emerg Radiol 27(6):737–745
38. Gulko E, Oleksik ML, Gomes W, Ali S, Mehta H, Overby P et al (2020) MRI brain findings in 126 patients with COVID-19: Initial observations from a descriptive literature review. AJNR Am J Neuroradiol 41(12):2199–2203
39. Yoon BC, Buch K, Lang M, Applewhite BP, Li MD, Mehan WA Jr, Leslie-Mazwi TM, Rincon SP (2020) Clinical and neuroimaging correlation in patients with COVID-19. AJNR Am J Neuroradiol 41(10):1791–1796

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:
▶ Convenient online submission
▶ Rigorous peer review
▶ Open access: articles freely available online
▶ High visibility within the field
▶ Retaining the copyright to your article

Submit your next manuscript at ▶ springeropen.com